Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 11, 1996, Pages 2655-2657

  Moghazeh, Soraya L ^a   Pan, Xi ^b   Arain, Taraq ^c   Stover, C Kendall ^c   Musser, James M ^b   Kreiswirth, Barry N ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; RIFALAZIL; RIFAMPICIN; RIFAPENTINE; RNA POLYMERASE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; ENZYME SUBUNIT; GENE MUTATION; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS;

EID: 0029861539     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.11.2655     Document Type: Article

References (21)

1. American Thoracic Society. 1992. Control of tuberculosis in the United States. Am. Rev. Respir. Dis. 146-1623-1633.
2. Bishai, W. R., N. M. H. Graham, S. Harrington, C. Page, K. Moore-Rice, N. Hooper, and R. E. Chaisson. 1996. Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N. Engl. J. Med. 334:1573-1576.
3. Bodmer, T., G. Zürcher, P. Imboden, and A. Telenti. 1995. Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycin-resistant Mycobacterium tuberculosis. J. Antimicrob. Chemother. 35:345-348.
4. Ellner, J. J., A. R. Hinman, S. W. Dooley, M. A. Fischl, K. A. Sepkowitz, M. J. Goldberger, T. M. Shinnick, M. D. Iseman, and W. R. Jacobs, Jr. 1993. Tuberculosis symposium: emerging problems and promise. J. Infect. Dis. 168:537-551.
5. Iseman, M. D. 1994. Evolution of drug-resistant tuberculosis: a tale of two species. Proc. Natl. Acad. Sci. USA 91:2428-2429.
6. Kapur, V., L.-L. Li, M. R. Hamrick, B. B. Plikaytis, T. M. Shinnick, A. Telenti, W. R. Jacobs, Jr., A. Banerjee, S. Cole, K. Y. Yuen, J. E. Claridge III, B. N. Kreiswirth, and J. M. Musser. 1995. Rapid Mycobaclerium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobaclerium tuberculosis by automated DNA sequencing. Arch. Pathol. Lab. Mecl. 119:131-138.
7. Kapur, V., L.-L. Li, S. Iordanescu, M. R. Hamrick, A. Wanger, B. N. Kreiswirth, and J. M. Musser. 1994. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase β subunit in rifampin-resistant Mycobaclerium tuberculosis strains from New York City and Texas. J. Clin. Microbiol. 32:1095-1098.
8. Kapur, V., T. S. Whittam, and J. M. Musser. 1994. Is Mycobacterium tuberculosis 15,000 years old? J. Infect. Dis. 170:1348-1349.
9. Klemens, S. P., and M. H. Cynamon. 1996. Activity of KRM-1648 in combination with isoniazid against Mycobaclerium tuberculosis in a murine model. Antimicrob. Agents Chemother. 40:298-301.
10. Kreiswirth, B. N., and A. R. Moss. 1996. Genotyping multidrug-resistant M. tuberculosis in New York City. In W. N. Rom and S. M. Garay (ed.), Tuberculosis. Little, Brown and Company, New York.
11. Lutfey, M., P. Della-Latta, V. Kapur, L. A. Palumbo, D. Gurner, G. Stotzky, J. Dobkin, A. Moss, J. M. Musser, and B. N. Kreiswirth. 1996. Independent origin of mono-rifampin-resistant M. tuberculosis in patients with AIDS. Am. J. Respir. Crit. Care Med. 153:837-840.
12. Miller, L. P., J. T. Crawford, and T. M. Shinnick. 1994. The rpoB gene of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38:805-811.
13. Musser, J. M. 1995. Antimicrobial agent resistance in mycobactcria: molecular genetic insights. Clin. Microbiol. Rev. 8:496-514.
14. Mustaev, A., E. Zaychikov, K. Severinov, M. Kashlev, A. Polyakov, V. Nikiforov, and A. Goldfarb. 1994. Topology of the RNA polymerase active center probed by chimeric rifampicin-nuclcotide compounds. Proc. Natl. Acad. Sci. USA 91:12036-12040.
15. National Committee for Clinical Laboratory Standards. 1990. Antimycobacterial susceptibility testing. Proposed standard M24-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
16. Nolan, C. M., D. L. Williams, M. D. Cave, K. D. Eisenach, H. El-Hajj, T. M. Hooton, R. L. Thompson, and S. V. Goldberg. 1995. Evolution of rifampin-resistance in human immunodeficiency virus-associated tuberculosis. Am. J. Respir. Crit. Care Med. 152:1067-1071.
17. Ohno, H., H. Koga, S. Kohno, T. Tashiro, and K. Hara. 1996. Relationship between rifampin MlCs for and rpoB mutations of Mycobaclerium tuberculosis strains isolated in Japan. Antimicrob. Agents Chemother. 40:1053-1056.
18. Telenti, A., P. Imboden, F. Marchesi, D. Lowrie, S. Cole, M. J. Colston, L. Matter, K. Schopfer, and T. Bodmer. 1993. Detection of rifampicin-resistant mutations in Mycobaclerium tuberculosis. Lancet 341:647-650.
19. Williams, D. L., C. Waguespack, K. Eisenach, J. T. Crawford, F. Portaels, M. Salfinger, C. M. Nolan, C. Abe, V. Sticht-Groh, and T. P. Gillis. 1994. Characterization of rifampin resistance in pathogenic mycobacteria. Antimicrob. Agents Chemother. 38:2380-2386.
20. Yamamoto, T., R. Amitani, K. Suzuki, E. Tanaka, T. Murayama, and F. Kuze. 1996. In vitro bacteriocidal and in vivo therapeutic activites of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:426-428.
21. Yamane, T., T. Hashizume, K. Yamashita, E. Konishi, K. Hosoe, T. Hidaka, K. Watanabe, H. Kawaharada, T. Yamamoto, and F. Kuze. 1993. Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chem. Pharm. Bull. 41:148-155.